Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2002 Oct;110(Suppl 5):757–759. doi: 10.1289/ehp.02110s5757

The molecular mechanisms of arsenic-induced cell transformation and apoptosis.

Zigang Dong 1
PMCID: PMC1241240  PMID: 12426127

Abstract

Arsenic is a well-documented human carcinogen associated with cancers of the skin, lung, liver, and bladder. Interestingly, arsenic has also been used as an effective chemotherapeutic agent in the treatment of certain human cancers. However, the mechanisms by which arsenic induces proliferation of cancer cells or cancer cell death are not well understood. We found that exposure of JB6 P+ cells to low concentrations of arsenic induces cell transformation, whereas higher concentrations of arsenic induce cell apoptosis. Arsenite induces phosphorylation of extracellular signal-regulated protein kinases (Erks) and c-Jun NH(2)-terminal kinases (JNKs). Arsenite-induced Erk activation was markedly inhibited by introduction of dominant-negative Erk2 into cells, whereas expression of dominant-negative Erk2 did not inhibit JNKs or mitogen-activated protein kinase Erk kinase 1/2. Furthermore, arsenite-induced cell transformation was blocked in cells expressing dominant-negative Erk2. In contrast, overexpression of dominant-negative JNK1 increased cell transformation even though it inhibited arsenite-induced JNK activation. Arsenic also induced AP-1 and nuclear factor kappa B (NF-kappaB) activation. Blocking NF-kappaB activation by dominant-negative inhibitory kappa Balpha inhibited arsenic-induced apoptosis and enhanced arsenic-induced cell transformation. Arsenic induced activation of JNKs at a similar dose range that was effective for induction of apoptosis in JB6 cells. In addition, we found that arsenic did not induce p53-dependent transactivation. Similarly, apoptosis induction was not different between p53 wild-type (p53(+/+)) or p53-deficient (p53(-/-)) cells. In contrast, arsenic-induced apoptosis was almost totally blocked by expression of a dominant-negative mutant of JNK. Taken together with previous findings that p53 mutations are involved in approximately 50% of all human cancers and nearly all chemotherapeutic agents kill cancer cells mainly by apoptotic induction, we suggest that arsenic may be a useful agent for the treatment of cancers with p53 mutations. These results suggest that the activation of Erks is required for arsenic-induced cell transformation, whereas the activation of JNKs and NF-kappaB is involved in arsenic-induced apoptosis of JB6 cells.

Full Text

The Full Text of this article is available as a PDF (172.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barchowsky A., Dudek E. J., Treadwell M. D., Wetterhahn K. E. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med. 1996;21(6):783–790. doi: 10.1016/0891-5849(96)00174-8. [DOI] [PubMed] [Google Scholar]
  2. Barchowsky A., Klei L. R., Dudek E. J., Swartz H. M., James P. E. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med. 1999 Dec;27(11-12):1405–1412. doi: 10.1016/s0891-5849(99)00186-0. [DOI] [PubMed] [Google Scholar]
  3. Bode Ann M., Dong Zigang. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol. 2002 Apr;42(1):5–24. doi: 10.1016/s1040-8428(01)00215-3. [DOI] [PubMed] [Google Scholar]
  4. Bode Ann, Dong Zigang. Apoptosis induction by arsenic: mechanisms of action and possible clinical applications for treating therapy-resistant cancers. Drug Resist Updat. 2000 Feb;3(1):21–29. doi: 10.1054/drup.2000.0114. [DOI] [PubMed] [Google Scholar]
  5. Chen C. J., Chuang Y. C., Lin T. M., Wu H. Y. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985 Nov;45(11 Pt 2):5895–5899. [PubMed] [Google Scholar]
  6. Chen G. Q., Shi X. G., Tang W., Xiong S. M., Zhu J., Cai X., Han Z. G., Ni J. H., Shi G. Y., Jia P. M. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997 May 1;89(9):3345–3353. [PubMed] [Google Scholar]
  7. Chen G. Q., Zhu J., Shi X. G., Ni J. H., Zhong H. J., Si G. Y., Jin X. L., Tang W., Li X. S., Xong S. M. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996 Aug 1;88(3):1052–1061. [PubMed] [Google Scholar]
  8. Chen N. Y., Ma W. Y., Huang C., Ding M., Dong Z. Activation of PKC is required for arsenite-induced signal transduction. J Environ Pathol Toxicol Oncol. 2000;19(3):297–305. [PubMed] [Google Scholar]
  9. Chen N. Y., Ma W. Y., Yang C. S., Dong Z. Inhibition of arsenite-induced apoptosis and AP-1 activity by epigallocatechin-3-gallate and theaflavins. J Environ Pathol Toxicol Oncol. 2000;19(3):287–295. [PubMed] [Google Scholar]
  10. Huang C., Bode A. M., Chen N. Y., Ma W. Y., Li J., Nomura M., Dong Z. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res. 2001 Jan-Feb;21(1A):261–267. [PubMed] [Google Scholar]
  11. Huang C., Ma W. Y., Li J., Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 1999 Jul 1;59(13):3053–3058. [PubMed] [Google Scholar]
  12. Huang C., Ma W. Y., Li J., Goranson A., Dong Z. Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem. 1999 May 21;274(21):14595–14601. doi: 10.1074/jbc.274.21.14595. [DOI] [PubMed] [Google Scholar]
  13. König A., Wrazel L., Warrell R. P., Jr, Rivi R., Pandolfi P. P., Jakubowski A., Gabrilove J. L. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood. 1997 Jul 15;90(2):562–570. [PubMed] [Google Scholar]
  14. Meng Z. Q., Meng N. Y. Effects of arsenic on blast transformation and DNA synthesis of human blood lymphocytes. Chemosphere. 2000 Jul;41(1-2):115–119. doi: 10.1016/s0045-6535(99)00397-5. [DOI] [PubMed] [Google Scholar]
  15. SOMMERS S. C., MCMANUS R. G. Multiple arsenical cancers of skin and internal organs. Cancer. 1953 Mar;6(2):347–359. doi: 10.1002/1097-0142(195303)6:2<347::aid-cncr2820060219>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  16. Smith A. H., Hopenhayn-Rich C., Bates M. N., Goeden H. M., Hertz-Picciotto I., Duggan H. M., Wood R., Kosnett M. J., Smith M. T. Cancer risks from arsenic in drinking water. Environ Health Perspect. 1992 Jul;97:259–267. doi: 10.1289/ehp.9297259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Zhao C. Q., Young M. R., Diwan B. A., Coogan T. P., Waalkes M. P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10907–10912. doi: 10.1073/pnas.94.20.10907. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES